Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
Items 401–500 of 1,001
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
Shirbhate, E., Singh, V. P., Jahoriya, V., Mishra, A., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115938 · Cited by 47
Histone-modifying genes as biomarkers in hepatocellular carcinoma.
Hung, S., Hui-hua, L., Yeh, K., & Chang, J. (2014) · PubMed · Cited by 52
SIRT1 and Neural Cell Fate Determination
Cai, Y., Xu, L., Xu, H., & Fan, X. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9158-6 · Cited by 48
“In addition, the most advanced SIRT1 inhibitor compound is selisistat (also known as EX-527 or SEN196), and it is being studied in a phase II clinical trial in Huntington’s disease patients (see the Siena Biotech website) [50, 51].”
BackgroundZhang, C., Tan, C. Y. J., Ge, J., Na, Z., Chen, G. Y. J., Uttamchandani, M., Sun, H., & Yao, S. Q. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307803 · Cited by 46
Cai, J., Wei, H., Hong, K. H., Wu, X., Cao, M., Zong, X., Li, L., Sun, C., Chen, J., & Ji, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.002 · Cited by 46
Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis
Ballabio, E., & Milne, T. A. (2012) · Cancers · doi:10.3390/cancers4030904 · Cited by 53
“Several recent excellent reviews have covered the topic of epigenetic inhibitors in general and MLL small molecule inhibitors in particular [16,268–273] and as such we will only briefly deal with this”
BackgroundProgress in the Development of non‐BET Bromodomain Chemical Probes
Theodoulou, N. H., Tomkinson, N. C. O., Prinjha, R. K., & Humphreys, P. G. (2016) · ChemMedChem · doi:10.1002/cmdc.201500540 · Cited by 45
Recent advances in musculoskeletal local drug delivery
Zhang, S., Xing, M. M. Q., & Li, B. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.01.043 · Cited by 47
“Besides the conventional anti-cancer drugs, new anti-cancer agents including small-molecule tyrosine-kinase inhibitors [76,77], drugs targeting epigenetic alterations [78], and immune-checkpoint inhibitors or monoclonal antibodies [79,80] have been developed to treat musculoskeletal cancers; however, most of them exhi…”
BackgroundHu, J., Tian, C.-Q., Damaneh, M. S., Li, Y., Cao, D., Lv, K., Yu, T., Meng, T., Chen, D., Wang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01094 · Cited by 47
Wang, Y., Sun, M., Wang, Y., Qin, J., Zhang, Y., Pang, Y., Yao, Y., Yang, H., & Duan, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113790 · Cited by 45
DeWoskin, V. A., & Million, R. P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4091 · Cited by 45
Weerachayaphorn, J., Amaya, M. J., Spirlì, C., Chansela, P., Mitchell-Richards, K., Ananthanarayanan, M., & Nathanson, M. H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.014 · Cited by 44
Cai, J., Wei, H., Hong, K. H., Wu, X., Zong, X., Cao, M., Wang, P., Li, L., Sun, C., Chen, B., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.028 · Cited by 44
Lyon, D., Elmore, L. W., Aboalela, N., Merrill, J. C., McCain, N. L., Starkweather, A. R., Elswick, R. K., & Jackson‐Cook, C. K. (2013) · Biological Research For Nursing · doi:10.1177/1099800413483545 · Cited by 50
Defining the Orphan Functions of Lysine Acetyltransferases
Montgomery, D. C., Sorum, A. W., & Meier, J. L. (2015) · ACS Chemical Biology · doi:10.1021/cb500853p · Cited by 44
Butler, K. V., Ma, A., Yu, W., Li, F., Tempel, W., Babault, N., Pittella-Silva, F., Shao, J., Wang, J., Luo, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01244 · Cited by 44
“The resulting compound, MS2177 (2) had an in vitro IC50 of 1.9 μM (σ = 1.05 μM, n = 4) in a scintillation proximity assay (Figure 1).”
BackgroundInfluentialSelf-citationRecent progress in developing selective inhibitors of protein methyltransferases
Kanıskan, H. Ü., & Jin, J. J. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.013 · Cited by 49
Wang, Q., Li, Y., Xu, J., Wang, Y., Leung, E. L., Liu, L., & Yao, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-08909-8 · Cited by 44
“2d) of BRD2-BD1(2)-RVX-208 complex systems.”
Barnash, K. D., James, L. I., & Frye, S. V. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2473 · Cited by 51
Epigenetic arginine methylation in breast cancer: emerging therapeutic strategies
Wang, S.-C., Dowhan, D. H., & Muscat, G. E. O. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0224 · Cited by 45
Selective Targeting of AF9 YEATS Domain by Cyclopeptide Inhibitors with Preorganized Conformation
Jiang, Y., Chen, G., Li, X., Liu, S., Tian, G., Li, Y., Li, X., Li, H., & Li, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10324 · Cited by 44
Iannelli, G., Milite, C., Marechal, N., Cura, V., Bonnefond, L., Troffer-Charlier, N., Feoli, A., Rescigno, D., Wang, Y., Cipriano, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00252 · Cited by 44
HCC-Related lncRNAs: Roles and Mechanisms
Shah, M., & Sarkar, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010597 · Cited by 52
“Recent studies have emphasized the significance of histone modifications in cellular plasticity and disease processes [24].”
BackgroundEpigenetic enzymes are the therapeutic targets for CD4+CD25+/highFoxp3+ regulatory T cells
Lopez‐Pastrana, J., Shao, Y., Chernaya, V., Wang, H., & Yang, X. (2014) · Translational research · doi:10.1016/j.trsl.2014.08.001 · Cited by 46
“So far, epigenetic modifications have been grouped into four main categories: DNA methylation, histone modification, small and non-coding RNAs, as well as chromatin remodeling (Figure 1) [55, 56].”
BackgroundHou, X., Du, J., Liu, R., Zhou, Y., Li, M., Xu, W., & Fang, H. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500762z · Cited by 44
Fujishiro, S., Dodo, K., Iwasa, E., Teng, Y., Sohtome, Y., Hamashima, Y., Ito, A., Yoshida, M., & Sodeoka, M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.087 · Cited by 43
Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain
Denny, R. A., Flick, A. C., Coe, J. W., Langille, J., Basak, A., Liu, S., Stock, I. A., Sahasrabudhe, P. V., Bonin, P. D., Hay, D. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01839 · Cited by 43
“21 4-{2-[5-(3,5-Dimethylisoxazol-4-yl)-1-(2-morpholin-4-ylethyl)-1H-benzimidazol-2-yl]ethyl}-phenol (9).”
Discovery of 1,8-acridinedione derivatives as novel GCN5 inhibitors via high throughput screening
Xiong, H., Han, J., Wang, J., Lu, W., Wang, C., Chen, Y., Lian, F., Zhang, N., Liu, J. Y.-C., Zhang, C., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.005 · Cited by 43
Influence of the microbiota on epigenetics in colorectal cancer
Sun, D., Chen, Y., & Fang, J. (2018) · National Science Review · doi:10.1093/nsr/nwy160 · Cited by 46
“Thus, various processes—such as DNA replication, repair, or transcription—can be regulated by the chromatin structure through local condensation or relaxation [13].”
BackgroundHistone methyltransferase DOT1L controls state-specific identity during B cell differentiation
Aslam, M. A., Alemdehy, M. F., Kwesi‐Maliepaard, E. M., Cagánová, M., Pardieck, I. N., van den Brand, T., Muhaimin, F. I., van Welsem, T., de Rink, I., Song, J., et al. (2021) · EMBO Reports · doi:10.15252/embr.202051184 · Cited by 52
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma
Kelly, G., Al‐Ejeh, F., McCuaig, R., Casciello, F., Kamal, N. A., Ferguson, B., Pritchard, A. L., Ali, S. S., da Silva, I. P., Wilmott, J. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3463 · Cited by 46
“Epigenetic modification of 87 histones has shown to be malignant drivers of several cancer types, including melanoma 88 (5-9).”
Perspectives in the development of hybrid bifunctional antitumour agents
Musso, L., Dallavalle, S., & Zunino, F. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.06.006 · Cited by 43
Epigenetic mechanisms governing the process of neurodegeneration
Qureshi, I., & Mehler, M. F. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.011 · Cited by 47
“In fact, much more selective small molecule, oligonucleotide and related treatment approaches are being developed to modulate the epigenome and are poised to revolutionize neurodegenerative disease treatment (Arrowsmith et al., 2012; Bader et al., 2010; Li et al., 2010).”
BackgroundThe roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells
Zhao, Z., Li, S., Song, E., & Liu, S. (2015) · Protein & Cell · doi:10.1007/s13238-015-0199-4 · Cited by 42
“Histone-modifiers are a new frontier for drug discovery, and lots of small molecular compound inhibitors have been developed for disease therapies, among which some have been investigated in Phase III of clinical trials (Arrowsmith et al., 2012).”
BackgroundA Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors
Teuscher, K. B., Zhang, M., & Ji, H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00923 · Cited by 44
“This protocol has successfully been used to characterize the inhibitors for bromodomain-containing proteins, the epigenetic readers of histone lysine acetylation, 10,11 and for the β -catenin/B-cell lymphoma 9 (BCL9) PPI, a key downstream effector of the canonical Wnt signaling pathway.”
The Structure and Function of the PRMT5:MEP50 Complex
Antonysamy, S. (2017) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-319-46503-6_7 · Cited by 43
Hyndman, K. A., & Knepper, M. A. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00313.2017 · Cited by 49
“These proteins are grouped based upon phylogenetic relationships determined 351 by (2) and (34) .”
BackgroundChemical Biology Approaches for Investigating the Functions of Lysine Acetyltransferases
He, M., Han, Z. H., Liu, L., & Zheng, Y. G. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201704745 · Cited by 44
Aboeldahab, A. M. A., Beshr, E. A. M., Shoman, M. E., Rabea, S. M., & Aly, O. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.021 · Cited by 44
Hii, L., Chung, F. F., Soo, J. S.-S., Tan, B. S., Mai, C., & Leong, C. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05504-5 · Cited by 43
Functionalized PAMAM constructed nanosystems for biomacromolecule delivery
Wong, K. H., Guo, Z., Law, M. K., & Chen, M. (2022) · Biomaterials Science · doi:10.1039/d2bm01677j · Cited by 43
Li, X., Tu, Z., Li, H., Liu, C., Li, Z., Sun, Q., Yao, Y., Liu, J., & Jiang, S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300371t · Cited by 43
Polycomb genes, miRNA, and their deregulation in B-cell malignancies
Wang, G. G., Konze, K. D., & Tao, J. (2015) · Blood · doi:10.1182/blood-2014-10-606822 · Cited by 46
Generating new neurons to circumvent your fears: the role of IGF signaling
Agís‐Balboa, R. C., & Fischer, A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1316-2 · Cited by 44
Intestinal differentiation involves cleavage of histone H3 N-terminal tails by multiple proteases
Ferrari, K. J., Amato, S., Noberini, R., Toscani, C., Fernández-Pérez, D., Rossi, A., Conforti, P., Zanotti, M., Bonaldi, T., Tamburri, S., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1228 · Cited by 41
“Their N-terminal regions protrude from the globular core of nucleosomes, are rich in lysine and arginine residues and serve as substrate for a complex pattern of regulatory post-translational modifications (PTMs) central to most biological processes (1), including a variety of human diseases like cancer, metabolic and…”
BackgroundZhan, Y., Kost‐Alimova, M., Shi, X., Leo, E., Bardenhagen, J., Shepard, H. E., Appikonda, S., Vangamudi, B., Zhao, S., Tieu, T. N., et al. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0026-4 · Cited by 44
A revised central dogma for the 21st century: All biology is cognitive information processing
Miller, W. B., Baluška, F., & Reber, A. S. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.05.005 · Cited by 51
A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors
Goracci, L., Deschamps, N., Randazzo, G. M., Petit, C., Passos, C. D. S., Carrupt, P., Simões‐Pires, C. A., & Nurisso, A. (2016) · Scientific Reports · doi:10.1038/srep29086 · Cited by 43
DNA Methylation–Targeted Drugs
Costa, E. M. D., McInnes, G., Beaudry, A., & Raynal, N. J. ‐. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000278 · Cited by 46
Kulka, L. A. M., Fangmann, P.-V., Panfilova, D., & Olzscha, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00425 · Cited by 44
Zn2+-Dependent Histone Deacetylases in Plants: Structure and Evolution
Yruela, I., Moreno–Yruela, C., & Olsen, C. A. (2021) · Trends in Plant Science · doi:10.1016/j.tplants.2020.12.011 · Cited by 41
“Overall, given the opposing effects of histone acetyltransferases (HATs), there is a strict balance between acetylation and deacetylation of histones that constitutes a pivotal regulatory mechanism of gene expression [8].”
BackgroundSaijo, H., Hirohashi, Y., Torigoe, T., Horibe, R., Takaya, A., Murai, A., Kubo, T., Kajiwara, T., Tanaka, T., Shionoya, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10571 · Cited by 43
Targeting cancer epigenetics: Linking basic biology to clinical medicine
Shinjo, K., & Kondo, Y. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.006 · Cited by 39
“Several other HDAC inhibitors are at different stages of clinical development for the treatment of many types of cancer [68, 69, 73].”
Ehmann, F., Amati, M. P., Salmonson, T., Posch, M., Vamvakas, S., Hemmings, R., Eichler, H., & Schneider, C. K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.14 · Cited by 40
Shao, Y., Chernaya, V., Johnson, C., Yang, W. Y., Cueto, R., Sha, X., Zhang, Y., Qin, X., Sun, J., Choi, E. T., et al. (2016) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-015-9664-y · Cited by 39
Zhu, X., Liu, X., Cheng, Z., Zhu, J., Xu, L., Wang, F., Qi, W., Yan, J., Liu, N., Sun, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep19926 · Cited by 39
Kuroki, S., Okashita, N., Baba, S., Maeda, R., Miyawaki, S., Yano, M., Yamaguchi, M., Kitano, S., Miyachi, H., Itoh, A., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007034 · Cited by 41
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 42
Li, N., Yang, L., Qi, X.-K., Lin, Y.-X., Xie, X., He, G.-P., Feng, Q.-S., Liu, L.-R., Xie, X., Zeng, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0789-1 · Cited by 41
Li, Y., Zhao, J., Gutgesell, L. M., Shen, Z., Ratia, K. M., Dye, K., Dubrovskyi, O., Zhao, H., Huang, F., Tonetti, D. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00456 · Cited by 41
The Histone Methyltransferase DOT1L Is Essential for Humoral Immune Responses
Kealy, L. C., Pietro, A. D., Hailes, L., Scheer, S., Dalit, L., Groom, J. R., Zaph, C., & Good‐Jacobson, K. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108504 · Cited by 46
Pietro, A. D., Polmear, J., Cooper, L., Damelang, T., Hussain, T., Hailes, L., O’Donnell, K., Udupa, V., Tian, M., Preston, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01077-y · Cited by 42
KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review
Chin, Y., & Han, S. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.991310 · Cited by 41
“Thus, the enzymes responsible for histone modifications can be a therapeutic target in the epigenetic area, which are classified as protein methyltransferases, lysine (K)-specific demethylases (KDMs), histone acetyltransferases (HATs), and histone deacetylases (HDACs) [2].”
BackgroundEpigenomics and the Microbiota
Alenghat, T. (2015) · Toxicologic Pathology · doi:10.1177/0192623314553805 · Cited by 39
“A broader concept of the epigenome has more recently been adopted to refer to the combination of histone and DNA modifications and associated proteins that package the genome and define the transcriptional program of a cell (Arrowsmith et al. 2012).”
BackgroundAli, M., Daze, K. D., Strongin, D. E., Rothbart, S. B., Rincón‐Arano, H., Allen, H. F., Li, J., Strahl, B. D., Hof, F. A., & Kutateladze, T. G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.669333 · Cited by 39
Gnad, F., Doll, S., Manning, G., Arnott, D. P., & Zhang, Z. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s8-s5 · Cited by 43
“We defined ERG families and their members by the presence of domains associated with writing, reading and erasing epigenetic marks as described [53].”
MethodChemical biology approaches to target validation in cancer
Blagg, J., & Workman, P. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.007 · Cited by 41
Epigenetic modulation in the treatment of atherosclerotic disease
Byrne, M. M., Murphy, R. T., & Ryan, A. W. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00364 · Cited by 39
Does bromodomain flexibility influence histone recognition?
Steiner, S., Magno, A., Danzhi Huang, A., & Caflisch, A. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.032 · Cited by 46
“In the human genome there are 46 proteins with a total of 61 different bromodomains, with up to six bromodomains per protein [3].”
BackgroundEpigenetic modulators from “The Big Blue”: A treasure to fight against cancer
Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.005 · Cited by 42
Hu, J., Wang, Y.-Q., Li, Y., Xu, L., Cao, D., Song, S., Damaneh, M. S., Wang, X., Meng, T., Chen, Y.-L., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.049 · Cited by 38
Patnaik, D., Estève, P., & Pradhan, S. (2018) · Oncotarget · doi:10.18632/oncotarget.25425 · Cited by 38
“These epigenetic effectors consist of writer, reader and eraser proteins that either generate, recognize or revert select histone or DNA modifications [1, 2].”
BackgroundJAGGED1/NOTCH3 activation promotes aortic hypermuscularization and stenosis in elastin deficiency
Dave, J. M., Chakraborty, R., Ntokou, A., Saito, J., Saddouk, F. Z., Feng, Z., Misra, A., Tellides, G., Riemer, R. K., Urban, Z., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci142338 · Cited by 42
“1172/JCI142338 4 Epigenetic modifications influence gene expression by altering chromatin accessibility and play a central role in regulating SMC behavior during vascular development and disease (33, 40).”
Wigle, T. J., Swinger, K. K., Campbell, J. E., Scholle, M. D., Sherrill, J., Admirand, E. A., Boriack‐Sjodin, P. A., Kuntz, K. W., Chesworth, R., Moyer, M. P., et al. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115575689 · Cited by 38
“Conversely, lysine methylation is “erased” by a family of 26 lysine demethylases (KDMs) that remove these methyl groups using two distinct oxidative mechanisms.(2) The methylation status of specific histone lysine residues recruits a variety of enzymes, transcription factors, and auxiliary proteins containing one or m…”
BackgroundInfluentialDesign and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors
Tashima, T., Murata, H., & Kodama, H. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.001 · Cited by 38
Zang, L., Kondengaden, S. M., Zhang, Q., Li, X., Sigalapalli, D. K., Kondengadan, S. M., Huang, K., Li, K. K., Li, S., Xiao, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18730 · Cited by 38
“While histone acetylation regulated by HDAC and their corresponding writer enzymes HATs, protein methylation is similarly regulated by protein lysine methyltransferases enzymes (PKMT), protein arginine methyltransferases (PRMT) and their corresponding demethylase enzymes [1, 28].”
BackgroundMozzetta, C., Pontis, J., & Ait‐Si‐Ali, S. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6116 · Cited by 39
“Indeed, a growing number of (pre)-clinical trials with epigenetic drugs, targeting histone methyltransferases, are starting to investigate the potential clinical relevance of the use of small-molecule inhibitors as a possible therapeutic approach to treat malignancies (4).”
Bahhaj, F. E., Denis, I., Pichavant, L., Delatouche, R., Collette, F. M., Linot, C., Pouliquen, D., Grégoire, M., Héroguez, V., Blanquart, C., et al. (2016) · Theranostics · doi:10.7150/thno.13725 · Cited by 41
“Post-translational modifications (PTM) of histone proteins and DNA methylation play major roles in the epigenetic regulation of gene expression.(1),(2) The enzymes regulating epigenetic modifications are classified as writers, erasers and readers, respectively adding, removing and “decoding” PTM.”
BackgroundPapakonstantinou, N., Ntoufa, S., Chartomatsidou, E., Kotta, K., Agathangelidis, A., Giassafaki, L.-P., Karamanli, T., Bele, P., Moysiadis, T., Baliakas, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9371 · Cited by 41
“[1, 2] The histone methyltransferase (HMT) Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core protein in the Polycomb Repressor Complex 2 (PRC2).”
BackgroundPinho, A. V., Mawson, A., Gill, A. J., Arshi, M., Warmerdam, M., Giry-Laterrière, M., Eling, N., Lie, T., Kuster, E., Camargo, S. M. R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11013 · Cited by 40
“SIRT1 is an interesting druggable target to halt tumor cell proliferation with successes in chronic myeloid leukemia [44] and with an inhibitor found to be safe in a clinical trial [45, 46].”
BackgroundStructure–Activity Relationships and Kinetic Studies of Peptidic Antagonists of CBX Chromodomains
Stuckey, J. I., Simpson, C. D., Norris-Drouin, J. L., Cholensky, S. H., Lee, J.-H., Pasca, R., Cheng, N., Dickson, B. M., Pearce, K. H., Frye, S. V., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00801 · Cited by 39
Identification of a peptide inhibitor for the histone methyltransferase WHSC1
Morrison, M. J., Boriack‐Sjodin, P. A., Swinger, K. K., Wigle, T. J., Sadalge, D., Kuntz, K. W., Scott, M. P., Janzen, W. P., Chesworth, R., Duncan, K. W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197082 · Cited by 37
Integrative Chemical Biology Approaches to Deciphering the Histone Code: A Problem-Driven Journey
Li, X., & Li, X. D. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00463 · Cited by 39
COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks
Kgatle, M., Lawal, I. O., Mashabela, G. T., Boshomane, T. M. G., Koatale, P. C., Mahasha, P. W., Ndlovu, H., Vorster, M., Rodrigues, H. G., Zeevaart, J. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752380 · Cited by 38
Histone Deacetylase Inhibitors: a Potential Epigenetic Treatment for Duchenne Muscular Dystrophy
Consalvi, S., Saccone, V., & Mozzetta, C. (2014) · Epigenomics · doi:10.2217/epi.14.36 · Cited by 41
Ma, M., Zhao, X., Chen, S., Zhao, Y., Yang, L., Yu, F., Qin, W., Li, L., & Jia, C. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b03673 · Cited by 38
Xu, B., Cai, L., Butler, J. M., Chen, D., Lu, X., Allison, D. F., Lu, R., Rafii, S., Parker, J. S., Zheng, D., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.020 · Cited by 39
“, 2009) and can be potentially druggable (Arrowsmith et al., 2012).”
Proteins and Proteoforms: New Separation Challenges
Regnier, F. E., & Kim, J. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b05007 · Cited by 36
Castellano, S., Spannhoff, A., Milite, C., Piaz, F. D., Cheng, D., Tosco, A., Viviano, M., Yamani, A., Cianciulli, A., Sala, M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301097p · Cited by 39
Choo, Q., Ho, P. C., Tanaka, Y., & Lin, H. (2013) · Molecules · doi:10.3390/molecules181114085 · Cited by 36
“Histone deacetylase (HDAC) inhibitors are a new class of anti-cancer agents that have attracted significant interest in drug discovery during the past 10-15 years [1].”
BackgroundInfluentialHow the flexibility of human histone deacetylases influences ligand binding: an overview
Deschamps, N., Simões‐Pires, C. A., Carrupt, P., & Nurisso, A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.004 · Cited by 39
SMN-Inducing Compounds For The Treatment Of Spinal Muscular Atrophy
Lorson, M. A., & Lorson, C. L. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.131 · Cited by 37
Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues
Jiang, H., Xing, J., Wang, C., Zhang, H., Yue, L., Wan, X., Chen, W., Ding, H., Xie, Y., Tao, H., et al. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02369c · Cited by 39
Insights for the Design of Protein Lysine Methyltransferase G9a Inhibitors
Mariasoosai, C., Dhayalan, A., Hsieh, H., & Coumar, M. S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0396 · Cited by 36
THE INNOVATIVE MEDICINES INITIATIVE: A PUBLIC PRIVATE PARTNERSHIP MODEL TO FOSTER DRUG DISCOVERY
Vaudano, E. (2013) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201303017 · Cited by 43
A multiconformer ligand model of inhibitor 53W bound to CREB binding protein bromodomain: 6dmj
Hudson, B. M., van Zundert, G., Keedy, D. A., Fonseca, R., Heliou, A., Suresh, P., Borrelli, K., Day, T., Fraser, J. S., & van den Bedem, H. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6dmj/pdb · Cited by 35
Willemsen, L., Prange, K. H. M., Neele, A. E., van Roomen, C. P. A. A., Gijbels, M. J., Griffith, G. R., den Toom, M., Beckers, L., Siebeler, R., Spann, N. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111703 · Cited by 40
“7 Targeting macrophage epigenetic modulators can be applied to guide macrophage activation in the right direction for a beneficial therapeutic outcome.”
BackgroundIndications to Epigenetic Dysfunction in the Pathogenesis of Common Variable Immunodeficiency
Rae, W. M. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0414-x · Cited by 39
“There are five classes of histone deacetylases (HDACs) based on enzyme structure (Arrowsmith et al. 2012).”
BackgroundKDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage
Castellini, L., Moon, E. J., Razorenova, O. V., Krieg, A. J., von Eyben, R., & Giaccia, A. J. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1281 · Cited by 37
“Although several histone posttranslational modifications are important components of the epigenome, acetyl and methyl marks on lysine residues are the most abundant and among the most widely studied (6).”
BackgroundLobo, J., Henrique, R., & Jerónimo, C. (2018) · Cancers · doi:10.3390/cancers11010006 · Cited by 35
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.